Who are Enclitide Chloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Amitiza, Amitiza (Lubiprostone), lubiprostone (Amitiza), Ivermectin 1% cream (IVM), Oral ivermectin, Spinosad Topical.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/enclitide-chloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Enclitide Chloride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enclitide Chloride (Enclitide Chloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chloride channel blocker. Area: Oncology.

phase 2 chloride channel blocker chloride channel Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Enclitide Chloride (Enclitide Chloride) — Merck Sharp & Dohme LLC. Enclitide chloride is a chloride channel blocker.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Enclitide Chloride TARGET	Enclitide Chloride	Merck Sharp & Dohme LLC	phase 2	chloride channel blocker	chloride channel
Amitiza	LUBIPROSTONE	Sucampo Pharma Llc	marketed	Chloride Channel Activator [EPC]	Chloride channel protein 2	2006-01-01
Amitiza (Lubiprostone)	Amitiza (Lubiprostone)	Brooke Army Medical Center	marketed	Chloride channel activator	ClC-2 chloride channel
lubiprostone (Amitiza)	lubiprostone (Amitiza)	Henry Ford Health System	marketed	ClC-2 chloride channel activator	ClC-2 chloride channel
Ivermectin 1% cream (IVM)	Ivermectin 1% cream (IVM)	Galderma R&D	marketed	Antiparasitic agent	Glutamate-gated chloride channels (invertebrate-specific)
Oral ivermectin	Oral ivermectin	University of Oxford	marketed	Macrocyclic lactone antiparasitic	Glutamate-gated chloride channels (GluCl)
Spinosad Topical	Spinosad Topical	Cipher Pharmaceuticals Inc.	marketed	Natural insecticide	Nicotinic acetylcholine receptors; GABA-gated chloride channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chloride channel blocker class)

Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enclitide Chloride — Competitive Intelligence Brief. https://druglandscape.com/ci/enclitide-chloride. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing